Scientists Found a Weight-Loss Signal Hidden in Your Own Body — No Drug Needed

Millions of people who try semaglutide — the active ingredient in Ozempic and Wegovy — quit within a year. Not because it stops working, but because of what it does to them: relentless nausea, constipation, and a loss of muscle mass that some researchers find genuinely alarming. So when Stanford Medicine pathologist Katrin Svensson published a study in Nature on March 5, 2025 describing a naturally occurring peptide that rivals semaglutide's appetite-suppressing power — with almost none of those side effects — the obesity research community paid close attention. The molecule is called BRP. It is twelve amino acids long and was found hiding inside a human gene no one had connected to hunger before.

Ozempic Works — But Not for Everyone

Semaglutide belongs to a class of drugs called GLP-1 receptor agonists. GLP-1, a naturally occurring hormone, tells your brain you are full and nudges the pancreas to release insulin. Semaglutide mimics that hormone extremely well — so well that the resulting weight loss numbers surprised even the people running the clinical trials. But the GLP-1 receptor is not confined to the brain. It shows up in the gut, the pancreas, the heart, and elsewhere, which is precisely why the drug slows digestion to a crawl, sometimes triggers vomiting, and strips lean muscle alongside fat. Svensson, an assistant professor in Stanford's department of pathology, wanted to know whether the body had other molecular tools for regulating appetite — ones that operated more selectively.

How Stanford's AI Dug Through 20,000 Genes

Finding BRP required a shortcut. The human genome encodes roughly 20,000 proteins, and each one can theoretically be chopped into dozens of smaller peptides — producing a combinatorial search space no lab could screen by hand. Svensson's team built a computer algorithm they called Peptide Predictor, which scanned every human protein-coding gene for the specific cut sites used by prohormone convertase 1/3, an enzyme already known to be linked to obesity in humans. They then filtered for proteins that get secreted outside the cell — a key property of hormones — and that have at least four cleavage sites. That narrowed the field from 20,000 proteins down to 373. From those, Peptide Predictor generated 2,683 candidate peptides. The team then screened 100 of them against lab-grown neurons to see which ones triggered a response.

Why Does BRP Cut Hunger Without Causing Nausea?

Here is where it gets interesting. When the researchers ran their 100 peptides through the neuronal screening, GLP-1 did what it was expected to do — it raised cell activity about three times above the baseline. BRP did something nobody predicted. It bumped activity up tenfold. Then the team traced where in the body BRP was actually working. Unlike semaglutide, which hits receptors scattered across multiple organs, BRP appears to act specifically in the hypothalamus — the region of the brain that governs hunger and energy balance. It activates a completely different set of neurons than GLP-1, through a completely different metabolic pathway. That anatomical specificity is almost certainly why it does not produce the gut disruption that drives so many Ozempic users to stop treatment. Whether that specificity holds in humans is the key open question, but the mechanism is clearly distinct.

What the Animal Results Actually Show

To be fair, the evidence so far is entirely from animals. But the results in those animals are hard to dismiss. A single intramuscular injection of BRP — given to both lean mice and minipigs before a meal — reduced food intake over the following hour by as much as 50% in both species. Minipigs were specifically chosen because their metabolism and eating behavior resemble humans more closely than mice do. Obese mice treated with daily BRP injections for 14 days lost an average of 3 grams; control animals gained about 3 grams over the same period. Almost all of that weight change was fat, not muscle — a contrast with semaglutide's well-documented lean mass losses. Crucially, behavioral monitoring found no changes in water intake, movement patterns, anxiety-like behavior, or bowel activity in any of the treated animals.

What Comes Before a Human Trial

Svensson has co-founded a company, Merrifield Therapeutics, to move BRP toward human clinical trials, which makes the timeline feel more concrete than the typical academic paper. But real questions remain before any trial can start. The team has not yet identified the receptor that BRP binds to — without knowing that, it is hard to predict what else in the body might respond to the molecule. The peptide also breaks down quickly, meaning researchers will likely need to engineer a modified version that stays active long enough for a practical dosing schedule; daily injections are manageable in a research setting but less appealing as a long-term drug regimen. And then there is the fundamental question of whether hypothalamic specificity — so clean and tidy in animal models — survives contact with human biology, which has a habit of being more complicated. The answer to that only comes from a trial.

• Targeted brain action — BRP appears to work specifically in the hypothalamus, which may explain why animals showed no nausea, constipation, or movement changes that typically signal gut disruption.
• Fat loss, not muscle loss — Weight reduction in treated mice came almost entirely from fat tissue, addressing one of the most medically troubling side effects linked to current GLP-1 drugs.
• AI-accelerated discovery — Without the Peptide Predictor algorithm, screening the human proteome for appetite-related peptides would have taken years of manual lab work, not months of computational search.

"The lack of effective drugs to treat obesity in humans has been a problem for decades. Nothing we've tested before has compared to semaglutide's ability to decrease appetite and body weight. We are very eager to learn if it is safe and effective in humans." — Svensson & Coassolo, Nature, 2025.